Fig. 1From: A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE)Patient disposition. aAll patients who received at least one dose of dapagliflozin. bPatients who were treated with dapagliflozin consistently for at least 90 days. T2DM, type 2 diabetes mellitusBack to article page